

Microbiology and Infectious Disease

Reviewed Preprint

Published from the original preprint after peer review and assessment by eLife.

[About eLife's process](#)Reviewed Preprint
posted

14 April 2023

Posted to bioRxiv

23 February 2023

Sent for peer review

23 February 2023

Extensive re-modelling of the cell wall during the development of *Staphylococcus aureus* bacteraemia

Edward J.A. Douglas, Nathanael Palk, Tarcisio Brignoli, Dina Altwiley, Marcia Boura, Maisem Laabei, Mario Recker, Gordon Y.C. Cheung, Ryan Liu, Roger C. Hsieh, Michael Otto, Eoin O'Brien, Rachel M. McLoughlin, Ruth C. Massey

School of Cellular and Molecular Medicine, University of Bristol, Bristol, BS8 1TD, UK • Department of Life Sciences, University of Bath, BA2 7AY, UK • Department of Biosciences, Università degli Studi di Milano, Milan, Italy • Centre for Ecology and Conservation, University of Exeter, Penryn Campus, TR10 9FE, UK • Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany • Laboratory of Bacteriology, National Institute of Allergy and Infectious Diseases (NIAID), US National Institutes of Health (NIH), Bethesda, Maryland, USA • Host Pathogen Interactions Group, School of Biochemistry and Immunology, Trinity College Dublin, Dublin 2, Ireland • Schools of Microbiology and Medicine, University College Cork, and APC Microbiome Ireland, Cork, Ireland

 (https://en.wikipedia.org/wiki/Open_access)

 (<https://creativecommons.org/licenses/by/4.0/>)

Abstract

Introductory Paragraph / Abstract

The bloodstream represents a hostile environment that bacteria must overcome to cause bacteraemia. To understand how the major human pathogen *Staphylococcus aureus* manages this we have utilised a functional genomics approach to identify a number of new loci that affect the ability of the bacteria to survive exposure to serum, the critical first step in the development of bacteraemia. The expression of one of these genes, *tcaA*, was found to be induced upon exposure to serum, and we show that it is involved in the elaboration of a critical virulence factor, the wall teichoic acids (WTA), within the cell envelope. The activity of this protein alters the sensitivity of the bacteria to cell wall attacking agents, including antimicrobial peptides, human defence fatty acids, and several antibiotics. This protein also affects the autolytic activity and lysostaphin sensitivity of the bacteria, suggesting that in addition to changing WTA abundance in the cell envelope, it also plays a role in peptidoglycan crosslinking. With TcaA rendering the bacteria more susceptible to serum killing, while simultaneously increasing the abundance of WTA in the cell envelope, it was unclear what effect this protein may have during infection. To explore this, we examined human data and performed murine experimental infections. Collectively, our data suggests that whilst mutations in *tcaA* are selected for during bacteraemia, this protein positively contributes to the virulence of *S. aureus* through its involvement in altering the cell wall architecture of the bacteria, a process that appears to play a key role in the development of bacteraemia.

eLife assessment

This **important** study uses an innovative genome-wide approach and targeted testing to identify *S. aureus* genes that affect susceptibility to serum, serum-derived antimicrobial products, and commonly used antibiotics. The findings are significant in that they highlight evidence of evolution of virulence determinants in the setting of exposure to host stressors expected to be present during bacteremia and antibiotic therapy. The evidence is **solid**, but the presentation could be improved by providing details that clarify the methods and highlighting the limited current understanding of the major target, *tcaA*.

Main Text

Staphylococcus aureus is an important human pathogen and a significant global health concern^{(1),(2)}. The most common interaction with its human host is as an asymptomatic coloniser; however, it frequently transitions to a pathogenic state with the ability to cause a wide range of diseases, ranging from relatively minor skin and soft tissue infections (SSTI) to more life-threatening incidents of endocarditis or bacteraemia^{(1),(2)}. *S. aureus* is notorious for producing a plethora of virulence factors ranging from pore forming toxins to various immune evasion strategies⁽³⁾. The toxicity of *S. aureus* is generally accepted as playing an important role during infection, with high toxicity isolates typically causing more severe symptoms and disease progression^{(4),(5)}. However, for the more invasive diseases such as bacteraemia and pneumonia, it has been shown that the causative isolates are often impaired in their toxin production and instead rely on alternative virulence approaches to cause disease, such as being able to better survive exposure to host immune defences^{(6),(7)}.

As the most severe type of infection caused by *S. aureus*, bacteraemia has a mortality rate of between 20 and 30%⁽⁸⁾, and despite infection control measures that have reduced the incidence of MRSA bacteraemia, the incidence of MSSA bacteraemia continues to increase in several countries, suggesting we have much to learn about this disease process. Entry into the bloodstream is the first step in the development of bacteraemia and represents a major bottle neck for the bacteria, whether they seed from an infection elsewhere in the body, or take a more direct route through an intravenous device. As a heavily protected niche, the bloodstream contains numerous humoral immune features with potent anti-staphylococcal activity, including antimicrobial peptides (AMPs) and host defence fatty acids (HDFAs)^{(9)–(12)}. However, the fact that cases of *S. aureus* bacteraemia occur demonstrates that these do not represent an impregnable force and that the bacteria can adapt to resist these defensive features.

In previous work we have pioneered the application of genome wide association studies (GWAS) to characterise bacterial virulence, where it has proven to be a powerful approach to define complex regulatory pathways^{(7), (13)–(17)}. In related work we have also begun to characterise a new category of *S. aureus* genes we refer to as MALs (mortality associated loci) and found that many of these are involved in serum survival⁽¹⁸⁾. Given the outstanding research questions surrounding the development of bacteraemia we performed a GWAS on a collection of 300 clinical isolates with respect to serum resistance. We found significant variability in how well individual isolates survive exposure to serum and identified seven novel effectors of this activity. Of particular note was the TcaA protein, which we have

further characterised and demonstrate that it is a critical protein for the bacteria involved in the remodelling of the bacterial cell wall during the development of bacteraemia.

Results

Survival of *S. aureus* upon exposure to human serum is a variable trait

The human bloodstream is a highly protected niche, and so to establish an infection in this environment the bacteria must evade many aspects of host immunity, such as the bacterial membrane damaging antimicrobial peptides (AMP) and host defence fatty acids (HDFAs) found in serum^{(9)–(12),(19)–(22)}. To examine the level of variability that exists in serum-susceptibility in natural populations of *S. aureus*, we exposed 300 clinical isolates to pooled human serum and quantified the proportion of each culture that survived. These 300 isolates represent the two major clones, as defined by multi-locus sequence typing: clonal complex 22 (CC22) and clonal complex 30 (CC30), that are responsible for the majority of MRSA cases in the UK and Ireland⁽¹⁴⁾. This collection is a unique resource as each strain has been sequenced, extensively phenotyped, and we have clinical metadata for many of the patients the bacteria were isolated from⁽¹⁴⁾. We found there to be similar levels of variability in the ability of the bacteria to survive exposure to human serum across the two CCs, both with a $>10^{(3)}$ fold difference between the most and least susceptible isolate with respect to the number of bacteria that survived (Fig. 1a & b).




Figure 1:

Serum susceptibility is multifactorial and varies widely across closely related *S. aureus* isolates. (a & b) The susceptibility of 300 bacteraemia isolates from clonal complexes CC22 and CC30 were exposed to human serum and their ability to survive this exposure quantified. The survival of each isolate was quantified in triplicate and dot represents the mean of these data. (c & d) Manhattan plots representing the statistical associations (on the y axis) between individual SNPs across the genome (on the x axis) and serum survival. The dotted red line represents the uncorrected significance threshold, and the dotted blue line represents the Sidak corrected (for multiple comparisons) threshold.

sents the uncorrected significance threshold, and the dotted blue line represents the Sidak corrected (for multiple comparisons) threshold.

Survival of *S. aureus* upon exposure to human serum is a polygenic trait

As the genome sequence for each of the 300 clinical *S. aureus* isolates was available we performed a GWAS (genome wide association study) to identify polymorphic loci or single nucleotide polymorphisms (SNPs) that associated with the level of susceptibility of isolates to serum. For this, the data from the two distinct clones were analysed independently, with population structure within the clones being accounted for ([Fig. 1c & d](#), [Tables 1a & 1b](#)). We applied both uncorrected and corrected (for multiple comparisons) significance thresholds to this analysis, as our previous work has demonstrated that the stringency of multiple correction approaches increases the likelihood of type II errors (i.e. false negative results). For the CC22 collection 12 loci were associated with serum survival and for the CC30s there were 32 associated loci ([Fig. 1c & d](#), [Tables 1a & 1b](#)).

Tables 1:

Loci associated with serum survival in the CC22 (Table 1a) and CC30 (Table 1b) collections. The SNP position is relative to the origin of replication in the reference genomes: HO 5096 0412 (CC22 and MRSA252 (CC30). Locus tags and where available gene names or putative protein functions have been provided. NTML refers to the mutant available in the Nebraska transposon library.

Table 1a

SNP position	CC22 locus tag	Description	p Value	Ref base	SNP base	Mutation	NTML
1945336	SAEMRSA15_RS09605	Intergenic	6.854	A	G	N/A	N/A
375179	SAEMRSA15_03110	<i>metE</i>	5.606	C	A	Arg-Leu	NE944
728154	SAEMRSA15_06310	<i>saeS</i>	5.553	T	A	Thr-Ser	ME1296
1053036	N/A	Intergenic	3.609	A	T	N/A	N/A
219764	SAEMRSA15_01760	putative oxidoreductase	3.576	G	A	Gly-Asp	NE312
2280500	SAEMRSA14_20910	alcohol dehydrogenase	2.257	A	T	Phe-Leu	NE1147
1196127	SAEMRSA15_10750	<i>yfhO</i>	2.212	C	T	Met-Ile	NE1597
408213	SAEMRSA15_03430	<i>guaA</i>	1.876	G	A	Ala-Thr	N/A
2492381	SAEMRSA15_23120	<i>tcyB</i>	1.645	A	G	Val-Ala	NE228
1514441	SAEMRSA15_13420	hypothetical protein	1.6	G	A	Thr-Ile	NE1349
2430758	SAEMRSA15_22540	<i>tcaA</i>	1.572	A	G	Phe-Ser	NE285
134276	SAEMRSA15J01100	hypothetical protein	1.358	A	g	N/A	NE599

Table 1b

SNP position	CC30 locus tag	Description	p Value	Ref base	SNP base	Mutation	NTML
101174	SAR0097	putative DNA binding protein	18.466	G	A	Asp-Asn	N/A
1188605	SAR1143	<i>arcC</i>	12.786	C	A	Pro-His	NE1719
900409	SAR0856	phosphoglycerate mutase	11.226	C	T	Arg-Cys	NE1422
2667418	SAR2584	<i>gntR</i>	10.263	C	T	Arg-Gln	NE1124
2421610	SAR2347	putative membrane protein	10.160	C	T	Leu-Phe	N/A
1687821	SAR1615	<i>aroK</i>	9.793	C	A	Arg-Ile	N/A
532944	SAR0495	<i>veg</i>	9.751	G	T	Ala-Ser	NE1703
1252982	SAR1203	<i>recG</i>	8.502	C	T	Ala-Val	NE1344
1816815	SAR1754	<i>clpX</i>	8.064	C	T	Gly-Ser	N/A
2206190	SAR2143	<i>ilvC</i>	8.050	G	A	Gly-Asp	NE1177
1443567	SAR1386	<i>trpA</i>	6.647	G	T	Ser-Ile	NE304
1167449	SAR1119	<i>uvrC</i>	6.439	A	G	Glu-Gly	NE1212
2442306	SAR2374	<i>ureC</i>	6.425	C	A	Ser-Arg	NE410
1784580	SAR1719	<i>tgt</i>	6.396	C	T	N/A	NE1885
880082	SAR0835	<i>est</i>	6.354	G	C	Gly-Ala	NE1122
1116463	SAR1070	<i>pdhD</i>	5.600	C	T	Ala-Val	NE1610
289265	SAR0248	<i>tarK</i>	5.324	T	A	Stop	NE362
1442353	SAR1385	<i>trpB</i>	4.910	C	T	Stop	NE310
364861	SAR0319	NADH flavin oxidoreductase	4.373	C	A	Ala-Ser	N/A
1963781	SAR1877	<i>menE</i>	4.315	T	C	Ser-Gly	N/A
1946567	SAR1856	<i>arsB2</i>	4.122	G	C	Gly-Ala	NE1484
1416353	SAR1364	iron-sulfur cluster biosynthesis protein	2.829	C	A	Trp-Vys	NE1910
1887414	SAR1810	<i>fhs</i>	2.741	C	T	Ala-Thr	NE706
1133886	SAR1088	<i>pcyA</i>	2.725	A	G	N/A	N/A
30969	SAR0023	<i>sasH</i>	2.507	A	C	Asn-Thr	NE295
330358	SAR0284	<i>essC</i>	2.486	C	T	Ala-Val	NE1484
2220348	SAR2151	<i>tex</i>	1.704	C	A	Asp-Tyr	NE1079
1468392	SAR1410	<i>hipO</i>	1.569	G	A	Arg-His	NE1688
1652613	SAR1582	<i>zwf</i>	1.556	A	G	Ile-Val	N/A
2744774	SAR2656	<i>nrmA</i>	1.549	G	A	Ser-Ile	NE1223
2370812	SAR2287	<i>lacR</i>	1.392	T	C	Glu-Gly	NE346

Functional validation of the GWAS results identifies seven novel genes that affect serum survival

Of the 44 loci associated with serum survival, there were transposon mutants available for 32 in the Nebraska library⁽²³⁾. To functionally verify our GWAS findings, each of these

mutants were significantly affected in this ability, and this effect was complemented by expressing the inactivated gene *in trans* (Fig. 2). The seven genes were *tcaA*, a gene associated with resistance to the antibiotic teicoplanin⁽²⁴⁾; *tarkK*, a gene involved in wall teichoic acid (WTA) biosynthesis⁽²⁵⁾; *gntR*, which encodes gluconate kinase⁽²⁶⁾; *ilvC*, which encodes ketol-acid reductoisomerase⁽²⁷⁾; *arsB*, which is an efflux pump involved in arsenic resistance⁽²⁸⁾; *yhfO*, which is involved in the glycosylation of lipoteichoic acid⁽²⁸⁾; and *pdhD*, which encodes a lipoamide dehydrogenase⁽³⁰⁾.




Figure 2:

Functional verification of loci involved in serum sensitivity of *S. aureus*. The effect of the inactivation of the genes associated serum sensitivity was examined using transposon mutants of strain JE2. Of the 32 mutants tested seven were significantly affected: (a) *tcaA*, (b) *tarkK*, (c) *gntR*, (d) *ilvC*, (e) *arsB*, (f) *yhfO* and (g) *pdhD*. The effect of the mutations on serum sensitivity was complemented by expressing the gene from the expression plasmid pRMC2 (e.g. the *tcaA* complementing plasmid is called *ptcaA*). The dots represent individual data points, the bars the

mean value, and the error bars the standard deviation. Significance was determined as * < 0.05, ** < 0.01, *** < 0.001.

The SNPs in the *tcaA* gene of the clinical isolates are associated with decreased serum sensitivity

The *tcaA* gene has previously been reported to be involved in conferring increased sensitivity to the antibiotic teicoplanin⁽²⁴⁾, and our findings suggest it also confers increased sensitivity to serum (Fig. 2a). To visualise the signal detected by the GWAS for this gene we have mapped the position of the clinical isolates with the *tcaA* SNPs onto a figure displaying the range of serum sensitivities of the collection (Fig. 3a). The majority of the isolates with the SNPs were less sensitive to serum, suggesting the SNPs negatively affects the activity of the protein. The most common SNP in the *tcaA* gene amongst the clinical isolates conferred a Phe (290) to Ser change in the protein sequence. Using AlphaFold⁽³¹⁾ we generated a structure for TcaA where it is predicted to be membrane bound with a single membrane spanning domain; to have a zinc finger presented intracellularly; with the majority of the protein including the Phe290 displayed extracellularly (Fig. 3b). Given that phenylalanines are frequently involved in protein-protein interactions⁽³²⁾ we examined the effect this

to that of the *tcaA* gene without the SNP. The TcaA protein with Ser at position 290 instead of Phe were slightly more resistant to serum killing, but not as affected as when the entire protein was inactivated, suggesting this change has a subtle effect on the serum sensitising activity of the protein (Fig. 3c).




Figure 3:

TcaA mutations affect resistance to both teicoplanin and serum across multiple *S. aureus* backgrounds.

(a) The individual clinical isolates with polymorphism in the *tcaA* gene are indicated (in red) on a graph displaying the range of serum survival of the collection. (b) The structure of the TcaA protein as predicted by AlphaFold. (c) The most common *tcaA* SNP decreases the sensitivity of *S. aureus* to serum. The dots represent individual data points, the bars the mean value, and the error bars

the standard deviation.

TcaA confers increased sensitivity to multiple antibacterial components of serum

To examine whether the effect of TcaA on serum resistance was specific to the JE2 background we transduced the *tcaA::tn* mutation from JE2 into *S. aureus* strains SH1000 and Newman. Attempts were made to transduce this mutation into a clinical CC22 isolate, but this lineage was refractory to any of the available transducing phage^{(33),(34)}. In all three backgrounds TcaA increased the sensitivity of the bacteria to serum (Fig. 4a) verifying that the effect was not limited to the JE2 background. To determine which aspects of human serum TcaA was conferring increased sensitivity to, we measured the relative ability of the wild type and mutant to survive exposure to some of the anti-bacterial factors found in serum: to the HDFA arachidonic acid, and to two AMPs: HNP-1 and LL37. The strains producing TcaA (i.e. the WT and complemented strain) were more sensitive to all three components of human serum (Fig. 4b-d). For the AMPs this sensitivity was significant after only 90 min exposure, whereas for arachidonic acid sensitivity was also evident after 90 minute, but was more prominent after overnight incubation.




Figure 4:

TcaA production confers increased sensitivity to several antibacterial components of serum. **(a)** The inactivation of the *tcaA* gene decreases the sensitivity of three *S. aureus* strains (i.e., JE2, Newman and SH1000) to serum. **(b)** TcaA production by the wild type and *ptcA* complemented strain confers increased sensitivity to arachidonic acid (100 μ M), **(c)** TcaA production by the JE2 wild type and *ptcA* complemented strain confers increased sensitivity to LL37 (5 μ g/ml) and **(d)** TcaA production by the wild type and *ptcA* complemented strain confers increased sensitivity to HNP-1 (5 μ g/ml). The dots represent individual data points, the bars the mean value, and the error bars the standard deviation. Significance was determined as * <0.05, ** <0.01, *** <0.001.

Although none of the individual antibacterial components of serum tested here are involved in *S. aureus* cell clumping, it is a possibility that some of the effects seen in serum is as a result of this activity, artificially amplifying the effect. To examine this the wild type and *tcaA* mutant were visually examined by microscopy in both PBS and serum where no differences in clumping was observed (Supplementary Fig. 1). Of the other GWAS identified genes, the *ilvC* mutant was less sensitive to arachidonic acid, the *yfhO* mutant was more resistant to HNP-1 and LL-37, while the *tarK*, *gntK*, *arsB* and *phdD* mutants were all more sensitive to HNP-1 and LL37 when compared to the JE2 wild type strain (Supplementary Fig. 2).

Wall teichoic acids contribute to the arachidonic acid sensitivity of TcaA producing strains

The antibacterial properties of HDFAs and AMPs share some common features in that they both penetrate through the cell wall and attack the bacterial membrane^{(9)–(12),(19)–(22)}. AMPs are positively charged molecules that rely on the relatively negative charge across the bacterial cell envelope to penetrate, and thus resistance is frequently acquired by changing the charge across the cell wall such that the AMPs are repelled^{(20),(21)}. Less is known about how HDFAs penetrate the cell wall; however, resistance is associated with changes in the abundance of wall teichoic acids (WTA) in the bacterial cell walls⁽²²⁾. WTA are hydrophilic and when present in the cell wall they are believed to be protective by interfering with the penetration of the hydrophobic HDFAs through to the bacterial membrane⁽²²⁾. It has also been shown that when the ligation of WTA to the cell wall is affected, such that they are instead released into the environment, this also decreases the sensitivity of the bacteria to HDFAs⁽¹¹⁾. With distinct modes of action and means of accessing their target, it is intriguing to consider how TcaA may be contributing to increasing the sensitivity of *S. aureus* to both these types of anti-bacterial molecules.

To examine whether the TcaA associated increase in sensitivity to arachidonic acid is a result of an increase in the abundance of WTA in the bacterial cell we extracted and quantified WTA from the wild type and *tcaA* mutant, where we found that the cell wall of the wild type had significantly more WTA when compared to the *tcaA* mutant cell extract (Fig. 5a & b; densitometric analysis of triplicate extractions can be seen in Supp. Fig. 3). We next quantified WTA in the bacterial supernatant, as recent work on a *S. aureus lcpA* mutant demonstrated that another WTA related means of altering sensitivity to arachidonic acid is to release the WTA the bacteria surface⁽¹¹⁾. We found significantly less WTA in the extract of the TcaA producing wild type strain compared to that of the *tcaA* mutant (Fig. 5a; densitometric analysis of triplicate extractions can be seen in Supp. Fig. 3), which could explain the observed difference in sensitivity to HDFAs. It was unclear from the previous work on LcpA how the released WTA by the *lcpA* mutant affects arachidonic acid sensitivity, and here we demonstrate that this mutant, like the *tcaA* mutant, is also less sensitive to human serum (Fig. 5d). One hypothesis is that the WTA can either sequester or inactivate HDFAs in the environment surrounding the bacteria, thereby neutralising them. To test this, we harvested the supernatant of the wild type JE2, the JE2 *tcaA* mutant, and the JE2 *lcpA* mutant from overnight growth. These supernatants were used to supplement fresh broth (at 10%) into which the wild type JE2 strain was inoculated. In the absence of any arachidonic acid JE2 grew equally well regardless of the supernatant supplement (Fig. 5e). However, in the presence of the supernatant of both the *tcaA* and *lcpA* mutant (both of which contain an abundance of released WTA), JE2 was able to grow in the presence of arachidonic acid; whereas when the JE2 supernatant was used as the supplement the bacteria were unable to grow (Fig. 5e). To further verify that soluble WTA can neutralise arachidonic we performed WTA extractions from an isogenic wild type and mutant of the *S. aureus* strain LAC where the mutant has had the *tarO* gene deleted and consequently does not produce any WTA (Fig. 5e). The incorporation of the wild type LAC WTA extract to broth at 2% created an environment in which JE2 could grow in the presence of arachidonic acid, whereas the equivalent WTA extract of the *tarO* mutant, which contains no WTA, did not (Fig. 6e). Together these data demonstrate that WTA in the environment can neutralise arachidonic acid, and this provides a likely explanation for the increased sensitivity to HDFAs associated with TcaA production.




Figure 5:

Wall teichoic acids are released from the cell wall in the *tcaA* mutant to affect resistance to HDFAs and AMPs. **(a)** WTA was extracted from both cells and supernatant of the wild type and *tcaA* mutant of *S. aureus* and visualised on an SDS-PAGE gel stained with 1 mg/ml Alcian blue. The *tcaA* mutant had significantly less WTA in the cell wall but more in the supernatant.

(b) The phosphate content of the cell wall WTA extracts was quantified, which verified that the *tcaA* mutant

has significantly less WTA. **(c)** The inactivation of the *lcpA* gene increases the sensitivity of *S. aureus* to killing by serum. **(d)** The wild type strain JE2 was grown in broth supplemented with supernatant of either itself (JE2), with that from a *tcaA* mutant, or with that from a *lcpA* mutant. These supernatants had no effect on the growth of JE2 in the absence of arachidonic acid. In the presence of arachidonic acid JE2 was unable to grow when supplemented with its own supernatant, however, when supplemented with the supernatant of the two mutants, which both contain soluble WTA, JE2 was able to grow. The addition of WTA extract from another *S. aureus* strain (LAC) also neutralised arachidonic acid, however an equivalent extract from an isogenic WTA mutant (LAC Δ *tarO*) did not. **(e)** The charge across the cell wall of the wild type and *tcaA* mutant was compared using cytochrome C, where the mutant was found to be less negatively charged. The dots represent individual data points, the bars the mean value, and the error bars the standard deviation. Significance was determined as * <0.05, ** <0.01, *** <0.001, **** <0.0001.




Figure 6:

TcaA confers increased sensitivity to teicoplanin. **(a)** The inactivation of the *tcaA* gene decreases the sensitivity of three distinct *S. aureus* strains (i.e., JE2, Newman and SH1000) to teicoplanin (0.5μg/ml). **(b)** The clinical isolates with polymorphisms in the *tcaA* gene were on average less sensitive to teicoplanin than those with the wild type gene. **(c)** The most common *tcaA* SNP decreases the sensitivity of *S. aureus* to teicoplanin. **(d)** The expression of the *tcaA* gene was quantified qRT-PCR in both subinhibitory and inhibitory concentrations of serum

and teicoplanin. There was a dose dependent effect on *tcaA* induction for all concentrations used. **(e)** Exposure of JE2 to inhibitory concentrations of human serum resulted in an increase in WTA abundance in the bacterial cell wall, an effect not seen when the *tcaA* mutant was exposed to serum. **(f)** Growth of JE2 in the presence of sub-inhibitory concentrations of teicoplanin (0.5 μg/ml) over a 24h period was quantified following pre-exposure to subinhibitory concentrations of human serum (2.5%), where preexposure to serum increased sensitivity to teicoplanin. The dots represent individual data points, the bars the mean value, and the error bars the standard deviation. Significance was determined as * <0.05, ** <0.01, *** <0.001, **** <0.0001.

The reduced abundance of WTA in the bacterial cell wall contributes to the resistance of *S. aureus* to AMPs

In addition to being hydrophilic, WTA is also predominantly negatively charged⁽²⁵⁾. Given that a change in charge across the bacterial cell wall is frequently associated with resistance to AMPs^{(19)–(21)}, and that the wild type strain has more WTA in its cell wall, this may explain the increased AMP sensitivity of the TcaA producing strain. To examine this, we incubated the bacteria with cytochrome C, which is positively charged and through its electrostatic-related ability binds to the bacterial cells, providing a measure of the charge across bacterial cell walls. Using this we found that the wild type strain bound significantly more cytochrome C and is therefore more negatively charged than the *tcaA* mutant, which explains the increase in AMP sensitivity we have found associated with TcaA production (Fig. 5e). Together these results explain how TcaA production affects the sensitivity of *S. aureus* to both HDFAs and AMPs. By retaining WTA within the cell wall, there is less released to sequester or inactivate the fatty acids from the environment, and due to their negative charge, increased amounts of WTA in the cell wall affects the charge across the cell wall and results in increased electrostatic attraction of the positively charged AMPs.

Serum induced *tcaA* expression increases both the abundance of WTA in the cell wall and the sensitivity *S. aureus* to teicoplanin

As mentioned previously, an additional interesting feature of the TcaA protein is that it has also been associated with changing the sensitivity of the bacteria to the antibiotic teicoplanin, although this has been reported to vary between strains^{(24),(35)}. To examine this for our strains we compared the ability of our three pairs of wild type and *tcaA* mutants (in strains JE2, Newman and SH1000) to grow in the minimum inhibitory concentration of teicoplanin for each wild type strain (Supp. Table 2), where TcaA production resulted in increased sensitivity to this antibiotic across all three strains (Fig. 6a). Minimum inhibitory concentrations (MICs) for teicoplanin have also been determined for these, where in each case the production of TcaA halves the MIC of the antibiotic (Supp. Table 2). To examine whether the clinical isolates with the SNPs in the *tcaA* gene associated with increased serum resistance also had altered teicoplanin sensitivity, we compared the ability of 12 clinical isolates containing the GWAS identified *tcaA* SNPs to grow in teicoplanin to that of 12 isolates from the same collection with the wild type gene sequence, i.e., without the polymorphism. The isolates with the polymorphism in the *tcaA* gene were on average less sensitive to teicoplanin (Fig. 6b). Using the pRMC2 complementing plasmid expressing either the wild type or SNP (conferring the Phe290-Ser substitution) containing *tcaA* gene, we demonstrated that this mutation significantly reduces the ability of the protein to sensitize the bacteria to serum (Fig. 6c), confirming that this mutation negatively affects the activity of the TcaA protein.

As TcaA has been shown to be upregulated when exposed to teicoplanin^{(24),(35)}, we examined whether serum would also induce its expression. The wild type JE2 strain was exposed to either sub-inhibitory (2.5% serum and 0.5µg/ml teicoplanin) or inhibitory (10% serum and 10µg/ml teicoplanin) concentrations of either serum or teicoplanin for 20 mins, total RNA was extracted and the transcription of the *tcaA* gene quantified by qRT-PCR. For both serum and teicoplanin, induction of expression of the *tcaA* gene was concentration dependent (Fig. 6d). Given the association of WTA abundance in the cell wall with *tcaA* expression described above (Fig. 5a-c) we next examined whether serum induced expression of *tcaA* would also result in an increase in abundance of WTA in the bacteria cell wall. Both the wild type and *tcaA* mutant were exposed to inhibitory concentrations of human serum for 90 mins and the WTA extracted from the cell walls, where serum exposure resulted in an increase in WTA for the wild type strain but not the *tcaA* mutant (Fig. 6e; densitometric analysis of triplicate extractions can be found in Supp Fig. 3). To examine whether serum induced increased expression of *tcaA* would affect sensitivity to teicoplanin, we exposed the wild type bacteria to a sub-inhibitory concentrations of serum (2.5%) and then incubated these overnight in a subinhibitory concentration of teicoplanin (0.5µg/ml). Pre-exposure to serum induced increased sensitivity to teicoplanin suggesting that induction of *tcaA* expression by the initial serum exposure was sufficient to induce cross-sensitivity to the antibiotic (Fig. 6f).

To verify this induction effect was not specific to the JE2 lineage a *tcaA::gfp* reporter plasmid was constructed and electroporated into JE2, SH1000, Newman and a clinical CC22 isolate EMRSA15. In each background serum, arachidonic acid and LL37 had a dose dependent effect on *tcaA* expression with the exception of LL37 and the EMRSA15 strain (Supplementary Fig. 4). These findings suggest that upon entry into the bloodstream and exposure to many of the antibacterial components of serum, expression of the *tcaA* gene is induced and this sensitizes *S. aureus* to killing by these components of serum.

The inactivation of tcaA alters the antibiotic resistance profile of S. aureus. There is emerging evidence that WTA play a role in cell division and peptidoglycan biosynthesis⁽³⁶⁾. In support of this, it has been reported that a *tarO* mutant, devoid of WTA, confers sensitization to β -lactam antibiotics due to mislocalization of the PBPs⁽³⁷⁾. As the target for teicoplanin is peptidoglycan, more specifically the terminal D-Ala-D-Ala residue of lipid II, we hypothesised that the increased ligation of WTA into the cell wall of the TcaA producing strain may affect peptidoglycan biosynthesis and assembly, and that this may be responsible for the change in sensitivity to teicoplanin. To test this further, we compared the sensitivity of the wild type and mutant to a range of peptidoglycan attacking antibiotics, where we found the TcaA producing wild type strain to be more sensitive to vancomycin, dalbavancin and oritavancin, all alternative members of the glycopeptide class of antibiotic, and ramoplanin, a glycolipodepsipeptide antibiotic (Supp. Fig. 5). However, TcaA production conferred decreased sensitivity to oxacillin, a β -lactam antibiotic that targets penicillin binding protein 2 and moenomycin a phosphoglycolipid antibiotic that inhibits the transglycosylase PBP enzymes and prevents the formation of peptidoglycan polymers (Supp. Fig. 5). This suggests that TcaA production affects the overall composition and structure of peptidoglycan in the wildtype strain.

To examine whether the crosslinking of peptidoglycan is affected by TcaA production, we tested the susceptibility of the wild type and *tcaA* mutant to lysostaphin, which is a glycylglycine endopeptidase capable of cleaving the pentaglycine crosslinks of peptidoglycan⁽³⁸⁾. We found that lysostaphin cleaved the cell wall of the wild type strain more slowly than for the *tcaA* mutant (Fig. 7a). We next performed a triton X100 induced autolysis assay where the wild type exhibited a slower rate of autolysis compared to the mutant, suggesting that the cell wall is stronger when TcaA is produced (Fig. 7b). Together these data suggest that the integrity of the peptidoglycan, in particular its crosslinking, is significantly altered when TcaA is produced. This provides a likely explanation for why the mutant is more resistant to teicoplanin, reduced crosslinking in the cell wall increases the number of off target D-ala D-ala which teicoplanin will bind to instead of reaching lipid II in the membrane and causing disruption to this. With changes to the quantity and composition of WTA and peptidoglycan associated with TcaA production, we sought to visualise the cell wall using transmission electron microscopy. We observed a clear difference in the density and structure of the outer layer of the bacterial cell wall between the wild type and *tcaA* mutant, confirming a role for TcaA in the structural integrity of the *S. aureus* cell wall (Fig. 7c, additional images in Supp. Fig. 6)).




Figure 7:

TcaA alters the structure of the *S. aureus* cell wall. **(a)** The rate of lysis in the presence of lysostaphin was assayed, where the strain producing was lysed at a slower rate than the *tcaA* mutant. A *pbp4* mutant was included as a control. **(b)** The rate of autolysis of the bacteria in the presence of Triton x100 was assayed where the TcaA producing strain lysed at a slower rate relative to the *tcaA* mutant. An autolysin (*atl*) mutant was included as a control. **(c)** Transmission electron micrograph (TEM) of a wild type JE2 and *tcaA* mutant cell at two magnifi-

cations showing the smooth and consistent density of the cell wall when TcaA is produced, compared to the rough and patchy density of the mutant cell wall.

Once established, TcaA contributes positively to the development of bacteraemia

Our data shows that expression of *tcaA* is induced upon exposure to serum, that this can sensitize the bacteria to serum killing but also increase the abundance of WTA in the cell envelope. From a pathogenicity perspective these activities would appear to be in conflict, with one making it less likely for a bacterium to cause bacteraemia (increased serum sensitivity) and the other making it more likely for a bacterium to cause bacteraemia (increased WTA in the cell envelope^{(39),(40)}). To understand this apparent dichotomy we first examined whether TcaA production only affected survival in serum, whereas in whole blood where other components of the human immune system may be present (e.g. complement, antibodies and phagocytes) that this effect may be lost. Using human blood from three donors, we demonstrated that TcaA production increase the sensitivity of the bacteria to whole blood killing (Supp. Fig. 7). We next interrogated our human clinical data, where in addition to the 300 bacteraemia strains that form the basis of this study we have an additional 176 *S. aureus* isolates, which has allowed us to include more genetic diversity to this analysis (i.e. from CC22 (n=138), CC30 (n=162), ST8 (n=132) and ST93 (n=44)). The source of these isolates was also available to us (i.e. bacteraemia (n=341), SSTI (n=80) or carriage (n=55)), as well as their genome sequences (Supplementary Table 1). We examined the distribution of nonsynonymous mutations in the *tcaA* gene across these, where it was present in 6% of the bacteraemia isolates compared with only 1.5% of non-bacteraemia isolates (n= 21/341 and 2/135 respectively; p = 0.03, in a Fisher's Exact test). However, when we examined the 30-day mortality rates for the 113 bacteraemia patients for whom we had this clinical data, the mortality rate of the proportion of patients infected with a *S. aureus* strain with the wild type *tcaA* gene was significantly higher compared to those infected with

a mutated *tcaA* gene (Fig. 8a & b) (2-tailed chi squared test: $p = 0.03$). So, although the incidence of mutations in *tcaA* appear to be relatively rare, that isolates with variant *tcaA* genes are enriched amongst those causing bacteraemia suggests that a functional TcaA may limit the propensity of *S. aureus* to cause a bloodstream infection, such that it acts as a selective force for mutants of this gene. However, once the bacteraemia has become established, TcaA positively contributes to the infection process, likely due to the increased abundance of WTA in the cell envelope, and the greater structural integrity of the cell wall.




Figure 8:

TcaA contributes to increased disease severity in mice and humans.

(a & b) A graph and contingency table showing data from 113 patient with *S. aureus* bacteraemia. The 30-day mortality rate was significantly higher for those infected with a *S. aureus* strain with a wild type *tcaA* gene compared to those with a mutated *tcaA* gene. **(c)** Mice were injected intravenously with 100 μ l of PBS containing an equal mixture of wild type and *tcaA* mutant ($2 \times 10^{(7)}$ CFUs of each). After 48 hrs, the ratio of the wild type and mutant were quantified and the relative virulence ratio calculated. In the blood and all organs tested the wild type bacteria had a competitive advantage over the mutant demonstrating its increased relative virulence. Mean $\pm$ s.d. The dots represent individual data points ($n=5$ per group), the bars the mean value, and the error bars the standard deviation. Significance was determined as * <0.05 , ** <0.01 , and *** <0.001 .

To experimentally test these human findings we utilised a mouse model of bacteraemia where the tail vein of C57/Bl6 mice are inoculated with $2 \times 10^{(7)}$ colony forming units (CFU) of bacteria to establish a bloodstream infection, where they seed from there into organs such as the liver spleen and kidneys. We performed mixed infections, where the wild type and mutant bacteria had to compete during the development of the infection within the mouse. The mice were infected with equal quantities of both bacteria and the change in ratio of the bacteria in the mouse blood, liver, spleen and kidney recorded after 48hr, which allowed the relative virulence ratio (RVR) of each bacterium to be calculated⁽⁴¹⁾. The RVR of the TcaA producing wild type strain was significantly higher than that of the mutant at a systemic level (Fig. 8c). As such, while the TcaA associated self-sensitization of the bacteria was not evident here, possibly due to the size of the inoculum level needed, once an infection has become established, TcaA contributes positively to disease severity as demonstrated by the wild type strain outcompeting the *tcaA* mutant.

Discussion

To develop novel therapeutic approaches for infectious diseases, we need to understand how microorganisms cause disease and evade the host's immune system. To address this, we have applied a population-based approach to analyse the pathogenicity of *S. aureus* and identified seven genes that affect the bacteria's ability to survive exposure to human serum, the first step in the development of bacteraemia. The dissection of the molecular detail of how these genes affect serum survival is underway to determine their potential for therapeutic intervention. However, our focus here has been on the *tcaA* gene where we show that its expression is induced upon exposure to serum, that it is involved in the ligation or retention of WTA in the cell wall, and that this renders the bacteria more susceptible to killing by both AMPs and HDFAs. We have also found that TcaA is associated with changes to the structural integrity of peptidoglycan, such that the bacteria are more susceptible to some antibiotics (e.g. teicoplanin) and less susceptible to others (e.g. oxacillin). It is interesting to note that our GWAS approach identified *tcaA* due to the presence of function altering SNPs amongst clinical isolates. Our human data suggests that bacteraemia and/or the antibiotics commonly used to treat it such as teicoplanin and vancomycin may impose a selective pressure on the bacteria to mutate this gene, due to the decreased sensitivity this confers to serum killing and to clinically relevant antibiotics. However, both our human and mouse data have confirmed, that once bacteraemia has become established, TcaA contributes positively to disease progression, likely due to its cell wall re-modelling activity.

The *tcaA* gene is part of a three gene locus alongside the *tcaR* gene, which is predicted to encode a transcriptional regulator, and the *tcaB* gene which is predicted to encode an efflux pump⁽²⁴⁾. This locus is also reported to be part of the *S. aureus* cell wall stimulon, following a number of studies that monitored the response of *S. aureus* to cell wall attack^{(42),(43)}. While work to understand the activity of each of the proteins encoded by the *tca* locus is underway, our data suggests that TcaA play a role in the ligation or retention of WTA within the cell wall, perhaps alongside the LcpA protein⁽¹¹⁾. How this is achieved is yet to be determined. TcaA may play a direct role in ligating WTA to the cell wall; it may play a role in cell wall turnover and the subsequent release of WTA and other cell wall macromolecules into the external environment; or it may interact and subsequently interfere with other cell wall biosynthetic processes that are responsible for WTA ligation. It is interesting to note that *tarK*, which is one of the other six genes associated here with serum survival is also involved in the biosynthesis of WTA. Additionally, *yfhO* which encodes an enzyme that glycosylates lipoteichoic acid (LTA) is also involved in serum resistance⁽²⁹⁾, providing further evidence for the importance of teichoic acid associated molecules to this aspect of the biology and pathogenicity of *S. aureus*. For TcaR, we hypothesise that it likely controls the transcription of the co-transcribed *tcaA* and *tcaB* genes, and may directly respond to the external stimulus of teicoplanin and serum as reported here. What is less clear is what role TcaB plays, as efflux pumps are more typically associated with increasing the resistance of a bacterium to an antibiotic, or other toxic molecules.

In addition to *tcaA* this study has identified one other locus (*yfhO*) that negatively affects serum survival, and added a further five loci (*tarK*, *gntR*, *ilvC*, *arsB*, and *pdhD*) to the list of genes that contribute positively to serum survival by protecting the bacteria from HDFAs and AMPs. This leads us to the questions of why *S. aureus* has loci in apparent conflict with regards to the survival of the bacteria during bacteraemia. It is perhaps through the consideration of the other ways in which *S. aureus* interact with humans that we may understand this. The vast majority of interactions that occur between *S. aureus* and humans is as a commensal in the human nose from which it can readily transmit. The five identified protective genes may therefore also protect the bacteria during colonisation, which would confer a selective advantage, and it is just an unfortunate coincidence that they also confer

increased survival in serum during the development of bacteraemia. While the focus of this work has been on the role of TcaA in serum, it is also worth considering what role it may have during colonisation of the nose, which involves the adherence of the bacteria to the nasal epithelium, to which WTA has a well-established role. It is therefore possible that TcaA enhances the ability of *S. aureus* cells to colonise the nose by retaining WTA within the cell wall. However, the role of TcaA in responsiveness to cell wall attack is as yet unclear, but perhaps it contributes to the competitiveness of *S. aureus* within the nasal microbiome in response to cell wall damage inflicted by competitors.

The evolution of the virulence of a pathogen is heavily dependent upon their mode of transmission, which for opportunistic pathogens raises interesting challenges. If within-host invasiveness limits between-host fitness by preventing them from transmitting to a new host, there are likely selective pressures acting on bacterial populations to evolve means of limiting their ability to cause invasive disease. However, if increased invasiveness facilitates enhanced within-host fitness, as the bacteria multiply and spread throughout the body, the ‘short-sighted evolution of virulence’ hypothesis proposed by Levin and Bull⁽⁴⁴⁾ could apply and may explain situations like *S. aureus* bacteraemia. We propose that TcaA may represent a system at the cusp of both these scenarios, in that it responds to cell wall attack by serum by making itself more susceptible to killing by serum, thereby potentially limiting its ability to cause bacteraemia, which could have long-term between host benefits. However, once established in the bloodstream and TcaA has remodelled the cell wall, the short-sighted view of virulence hypothesis applies where the bacteria survive and thrive, allowing them to cause a successful bacteraemia.

Entry into the bloodstream to establish an infection has long been considered a significant bottle neck for the bacteria, but until now, the stringency of this bottleneck was believed to be a result of the onslaught of all the immune mechanisms present in blood. Here we suggest that *S. aureus* may contribute to this bottleneck by responding to serum induced cell wall damage by further sensitizing itself to this attack as part of the pathway towards increasing their pathogenic capabilities by remodelling the cell wall. Our findings presented here opens up an entirely novel aspect to the biology of a major human pathogen and brings into question the appropriateness of the term ‘opportunistic’ when we refer to such highly effective bacterial pathogens.

Materials and Methods

Bacterial Strains and Growth Conditions

A list of the genetically amenable bacterial strains and mutants can be found in [Table 3](#), and the clinical strains are listed in Supplementary Table 1. All strains were cultured in Tryptic soy broth (TSB) for 18 h at 37°C with shaking. Nebraska transposon mutant library (NTML)⁽²³⁾ mutants were selected for using erythromycin (5 µg/ml). For the complemented pRMC2⁽⁴⁵⁾ strains, chloramphenicol (10 µg/ml) and anhydrous tetracycline (200 ng/ul) were added to the media where indicated.

Table 2.

Strains used in this study.

Strain	Description	Reference
JE2	USA300; CA -MRSA, type IV SCCmec; lacking plasmids p01 and p03; wild -type strain of the	23

	NTML	
JE2 <i>tcaA:tn</i>	<i>tcaA</i> transposon mutant in JE2	23
JE2 <i>tcaA:tn</i> pRMC2	<i>tcaA</i> transposon mutant in JE2 transformed with empty pRMC2 vector	This study
JE2 <i>tcaA:tn ptcaA</i>	<i>tcaA</i> transposon mutant complemented with <i>tcaA</i> gene housed in pRMC2 expression plasmid	This study
JE2 <i>tarK:tn</i>	<i>tarK</i> transposon mutant in JE2	23
JE2 <i>tarK:tn</i> pRMC2	<i>tarK</i> transposon mutant in JE2 transformed with empty pRMC2 vector	This study
JE2 <i>tarK:tn ptarK</i>	<i>tarK</i> transposon mutant complemented with <i>tarK</i> gene housed in pRMC2 expression plasmid	This study
JE2 <i>gntR:tn</i>	<i>gntK</i> transposon mutant in JE2	23
JE2 <i>gntR:tn</i> pRMC2	<i>gntK</i> transposon mutant in JE2 transformed with empty pRMC2 vector	This study
JE2 <i>pgntR</i>	<i>gntK</i> transposon mutant complemented with <i>gntK</i> gene housed in pRMC2 expression plasmid	This study
JE2 <i>ilvC:tn</i>	<i>ilvC</i> transposon mutant in JE2	23
JE2 <i>ilvC:tn</i> pRMC2	<i>ilvC</i> transposon mutant in JE2 transformed with empty pRMC2 vector	This study
JE2 <i>ilvC:tn pilvC</i>	<i>ilvC</i> transposon mutant complemented with <i>ilvC</i> gene housed in pRMC2 expression plasmid	This study
JE2 <i>arsB:tn</i>	<i>arsB</i> transposon mutant in JE2	23
JE2 <i>arsB:tn</i> pRMC2	<i>arsB</i> transposon mutant in JE2 transformed with empty pRMC2 vector	This study
JE2 <i>arsB:tn parsB</i>	<i>arsB</i> transposon mutant complemented with <i>arsB</i> gene housed in pRMC2 expression plasmid	This study
JE2 <i>yfhO:tn</i>	<i>yfhO</i> transposon mutant in JE2	23

JE2 <i>yfhO::tn</i> pRMC2	<i>yfhO</i> transposon mutant in JE2 transformed with empty pRMC2 vector	This study
JE2 <i>yfhO::tn</i> <i>pyfhO</i>	<i>yfhO</i> transposon mutant complemented with <i>yfhO</i> gene housed in pRMC2 expression plasmid	This study
JE2 <i>pdhD::tn</i>	<i>pdhD</i> transposon mutant in JE2	23
JE2 <i>pdhD::tn</i> pRMC2	<i>pdhD</i> transposon mutant in JE2 transformed with empty pRMC2 vector	This study
JE2 <i>pdhD::tn</i> <i>ppdhD</i>	<i>pdhD</i> transposon mutant complemented with <i>pdhD</i> gene housed in pRMC2 expression plasmid	This study
RN4220	Restriction deficient mutant of 8325-4	46
DC10B	Δdcm mutant in <i>E. coli</i> DH10B (K12)	34
Mach1	One Shot™ Mach1™ T1 Phage-Resistant Chemically Competent <i>E. coli</i> .	Commercially available
SH1000	MSSA, laboratory strain, 8325-4 with a repaired <i>rsbU</i> gene; SigB positive.	47
SH1000 <i>tcaA::tn</i>	<i>tcaA</i> transposon mutant in SH1000	This study
Newman	MSSA, laboratory strain isolated from human infection	48
Newman <i>tcaA::tn</i>	<i>tcaA</i> transposon mutant in Newman	This study
<i>tcaA::tn</i> <i>ptcaASNP</i>	<i>tcaA</i> transposon mutant complemented with <i>tcaA</i> gene harbouring F290S SNP housed in pRMC2 expression plasmid	This study
<i>mprF::tn</i>	<i>mprF</i> transposon mutant in Newman	23
$\Delta lcpA$	In frame unmarked deletion of <i>lcpA</i> generated by allelic exchange	11
LAC	CA-MRSA USA300 type IV SCCmec	49

$\Delta tarO$	<i>tarO</i> KO mutant in LAC	50
JE2 pSB2019: <i>tcaA</i>	JE2 transformed with the pSB2019: <i>tcaA</i> reporter fusion	This study
SH1000 pSB2019: <i>tcaA</i>	SH1000 transformed with the pSB2019: <i>tcaA</i> reporter fusion	This study
Newman pSB2019: <i>tcaA</i>	SH1000 transformed with the pSB2019: <i>tcaA</i> reporter fusion	This study
EMRSA15 pSB2019: <i>tcaA</i>	SH1000 transformed with the pSB2019: <i>tcaA</i> reporter fusion	This study

Serum & Blood Survival Assay

Normal human serum was prepared from blood obtained from 8 healthy volunteers using Serum CAT tubes (BD). Blood was allowed to clot for 30 mins at room temperature followed by 1h incubation on ice. Serum was extracted following two rounds of centrifugation at 700 x g at 4°C for 10 min. Serum from individual donors were pooled, aliquoted and immediately stored at -80°C. The bacteria were grown overnight, and their density normalised to an OD_{600nm} of 0.1 and 20 µl used to incubate in 180 µl 10% pooled human serum (diluted in PBS) for 90 min at 37°C with shaking. Serial dilutions were plated on tryptic soy agar (TSA) to determine CFUs. The same number of bacterial cells inoculated into PBS, diluted, and plated acted as a control. Survival was determined as the percentage of CFU in serum relative to the PBS control. Relative survival was determined through normalisation to JE2, which is presented at 100% in the graphs. The survival of each bacterial isolate was measured in triplicate and the mean of these data presented here.

Gwas

Genome-wide association mapping was conducted using a generalized linear model, with capsule production as the quantitative response variable. We accounted for bacterial population substructure by adding to the regression model the first two components from a *principal component decomposition* of SNP data for each set of clinical samples (CC22 and CC30). The first two components accounted for 32% and 40% of the total variance for CC22 and CC30, respectively. In both cases, three distinct clusters were identified. We further considered a third model where we used cluster membership as covariates in our regression model, where clusters were defined using K-means clustering analysis (setting K=3); this, however, yielded identical results to the one based on PCA components. In total, 2066 (CC22) and 3189 (CC30) unique SNPs were analysed, the majority of which were subsequently filtered out for exhibiting a minor allele frequency (maf) of <0.03, reducing the data to 378 and 1124 SNPs, respectively. The P-values reported in [Tables 1a](#) and [b](#) are not corrected for multiple comparison, however the Sidak method was used to correct for multiple comparisons and both significance thresholds are indicated in the Manhattan plots.

Genetic manipulation of bacterial strains

Wildtype genes were amplified by PCR from JE2 genomic DNA using the primers shown in table 4 and KAPA HiFi polymerase (Roche). The PCR product was cloned into the tetracycline inducible plasmid pRMC2⁽⁴⁵⁾ using *KpnI* and *SacI* restriction sites and T4 DNA ligase (NEB). This was transformed into RN4220 and eventually into the respective NTML mutants through electroporation.

Table 3.

PCR primers used in this study.

Primer name	Primer sequence 5'-3'
<i>tcaA</i> FW	ataagcttgatggtaccaattgaagaggaacagaattgag
<i>tcaA</i> RV	tgaattcgagctcagatcatgacacatgcatcttatttaag
<i>takK</i> FW	ataagcttgatggtacctttaataaaccgatggggg
<i>takK</i> RV	tgaattcgagctcagatgcaagtaatatatgccaacattag
<i>gntK</i> FW	ataagcttgatggtaccgatgtcgtgtaatgaaggagtg

<i>gntK</i> RV	tgaattcgagctcagatttcttctttcattttaattcaacc
<i>ilvC</i> FW	ataagcttgatggtacccgaaacacaaaatatttaatttttg
<i>ilvC</i> RV	tgaattcgagctcagattaacaactcctcattgtaggtctatc
<i>arsB2</i> FW	ataagcttgatggtaccgtcataacctaagactggtgaatgc
<i>arsB2</i> RV	tgaattcgagctcagatgagttgcctgtacataaaaataaattg
<i>yfhO</i> FW	ataagcttgatggtacctgaaagttgaggataatgttgtg
<i>yfhO</i> RV	tgaattcgagctcagatgtagcaacattattttgtcttgc
<i>pdhD</i> FW	ataagcttgatggtaccgaattattattaatggaggggtaaaac
<i>pdhD</i> RV	tgaattcgagctcagatgcatgtcacatgttaacgatatctc

Site directed mutagenesis of the *tcaA* gene

Site directed mutagenesis was used to mutate the WT *tcaA* gene (Phe290) to the SNP *tcaA* (Ser290). Primers (5' ttttcaagttTcaaaacgtatggtc 3', 5' atacgttttgaAactgaaaatgcc 3') were designed to have a complementary overlap of 21 nucleotides at the 5' end, with the nucleotide to be mutated at the centre of the overlap (the primers had non complementary regions at the 3' end to facilitate annealing on the template). The *ptcaA* template was diluted to 33 ng/μl, and 1ul was amplified using these primers and Phusion DNA polymerase. The

PCR product was subsequently checked by agarose gel electrophoresis and was treated with 1 µl of DpnI directly in the PCR mix for 1 h at 37°C. Then 1 µl of the mixture was used to transform One Shot™ Mach1™ T1 (ThermoFisher) competent cells by heat shock then into RN4220 and finally *tcaA::tn* by electroporation.

Phage transduction of the *bursa aurealis* transposon

The *tcaA bursa aurealis* transposon was phage transduced using the *S. aureus* phage Φ11⁽⁵¹⁾. The phage lysate of the donor strain (*tcaA::tn*) was prepared as follows: The donor strain was grown overnight in TSB for 18 h at 37°C with shaking. Two hundred microlitres of overnight culture was added to 25 ml of TSB containing 250 µl 1M MgSO₄, 250 µl 1M CaCl₂, 100 µl of Φ11 and left at 37°C with shaking until complete lysis was observed. The culture was subsequently pelleted at 12000 x g for 3 min. The supernatant containing the lytic phage was filtered sterilised and stored at 4°C. Next, recipient strains (Newman and SH1000) were grown overnight in 20 ml of LK broth (1% Tryptone 0.5% Yeast Extract, 0.7% KCl) and pelleted at 2500 x g for 10 min. The supernatant was removed, and the pellets resuspended in 1 ml of fresh LK broth. Two reactions were then set up, one containing phage and one as a non-phage control. To the tube containing the phage add: 250 µl of the recipient strain (SH1000 or Newman), 250 µl of phage lysate and 750 µl of LK broth containing 10 mM CaCl₂. To the tube containing the non-phage control add: 250 µl of the recipient strain (SH1000 or Newman) and 1 ml of LK broth containing 10 mM CaCl₂. Both reactions were incubated for 25 min at 37°C without shaking followed by 15 min at 37°C with shaking. Five hundred microlitres of ice cold 20 mM sodium citrate was added followed by centrifugation at 10000 x g for 10 min. Pellets were resuspended in 500 µl of 20 mM sodium citrate and incubated on ice for 2 h. One hundred microlitres of culture was plated out on TSA containing 5 µg ml⁻¹ erythromycin to select for the transposon. For the SH1000 phage transduction 100 µl was also plated out on oxacillin TSA plates as an added control to ensure there was no contamination of the phage lysate with JE2 *tcaA::tn*.

Growth inhibition assays

To determine the relative inhibition of growth of the wild type and *tcaA* mutant by antibiotics a broth microdilution method was used⁽⁵²⁾. Briefly, overnight cultures were normalised to an OD_{600nm} of 0.1 in cation adjusted Mueller Hinton broth (MHB++) and 20 µl of resultant suspension used to inoculate 180 µl of fresh MHB++ containing a 1:2 dilution series of either arachidonic acid or teicoplanin (Sigma). The ability of the bacteria to survive the antibiotics was determined by quantifying bacterial growth (OD_{600nm}) using a CLARIOstar plate reader (BMG Labtech). For Fig. 2b 0.5 µg/ml teicoplanin was used for the clinical CC22 isolates and for Fig. 2d: 1 µg/ml was used for the JE2 pair, 2 µg/ml for the Newman pair and 4 µg/ml for the SH1000 pair.

Antimicrobial peptide susceptibility

Antimicrobial peptide susceptibility Human neutrophil defensin-1 (hNP-1) (AnaSpec Incorporated, California, USA) and LL-37 (Sigma) susceptibility assays were performed as described previously⁽⁵³⁾. Briefly, overnight cultures were normalised to an OD_{600nm} of 0.1 and incubated with 5 µg/mL of hNP-1 or LL-37 for 2 h at 37 °C. Serial dilutions were plated on tryptic soy agar (TSA) to determine CFUs. The same number of bacterial cells inoculated into PBS, diluted, and plated acted as a control. Survival was determined as the percentage of CFU on exposure to either LL-37 or HNP-1 relative to the PBS control. Relative survival was determined through normalisation to JE2.

mRNA extraction

Overnight cultures were back diluted to an OD_{600nm} of 0.05 in 50 ml of fresh TSB and grown to an OD_{600nm} of 2. Two hundred micro litres of either PBS, 25% serum (final concentration 2.5%, sub-inhibitory), 5 µg/ml teicoplanin (final concentration 0.5 µg/ml, sub-inhibitory), 100% serum (final concentration 10%, inhibitory), or 100 µg/ml teicoplanin (final concentration 10 µg/ml, inhibitory) was added to 1.8 ml of bacterial culture and incubated for 20 min. RNA was extracted by Quick-RNA Fungal/Bacterial Miniprep Kit (Zymo Research) according to the manufacturer's instructions. RNA integrity was checked by running 5 µl aliquot of the RNA on a 1% agarose gel and observing the intensity of the ribosomal RNA (rRNA). RNA samples were treated by TURBO™ DNase (Invitrogen) to eliminate any genomic DNA contamination. To verify that the samples were free from any DNA contamination, RNA samples were subjected to RT-qPCR alongside a no template control and 2.5 ng of a known JE2 genomic DNA and threshold rates compared.

qRT-PCR

To quantify the expression of the *tcaA* RT-qPCR was performed using the housekeeping *gyrB* gene as a control. Complementary DNA (cDNA) was generated from mRNA using qScript® cDNA Synthesis Kit (Quantabio). Following the manufacturers protocol the cDNA was used as a template for the RT-qPCR reaction. Primers used were as follows *gyrB* FW 5' ggtgactgcattagatgtaaac 3', *gyrB* RV 5' ctgcttctaaaccttctaatacttgatttg 3', *tcaA* FW 5' tagtttgcgcttcaggtg 3', *tcaA* RV 5' tgtggacataaatttgatagtcgtc 3'. The RT-qPCR reaction was performed as follows: 10 µl 2x KAPA SYBR Mix, 1 µl of 10 µM forward primer, 1 µl of 10 µM reverse primer, 5 µl cDNA and RNase-free water up to a total of 20 µl volume. The RT-qPCR was performed on a Mic qPCR cycler (bio molecular systems) and the cycling conditions consisted of an initial denaturation step of 95°C for 2 min, followed by 40 cycles of two step cycling: 95°C 15 s, 60°C 1 min. RT-qPCR was carried out in technical triplicate for each sample and 3 biological repeats. The ratio of *tcaA* to *gyrB* transcript number was calculated using the using the $2^{-\Delta\Delta Ct}$ method⁽⁵⁴⁾.

WTA preparations

Crude WTA from murein sacculi was extracted for analysis by PAGE using adaptations of a previously described methodology^{(55),(56)}. Overnight cultures were washed once in buffer 1 (50 mM MES, pH 6.5) followed by centrifugation at 5,000 g. Cells were resuspended in buffer 2 (4% [wt/vol] SDS, 50 mM MES, pH 6.5) and boiled for 1 h. Sacculi were centrifuged at 5,000g and washed once in buffer 1, once in buffer 2, once in buffer 3 (2% NaCl, 50 mM MES, pH 6.5), once more in buffer 1 and finally resuspended in digestion buffer (20 mM Tris-HCl pH 8.0, 0.5% [w/v] SDS). To the digestion buffer suspension, 10 µl of proteinase K solution (2 mg/ml) was added and incubated on a heat block 50°C for 4 h at 1,400 rpm. Sacculi were centrifuged at 16,000 g and washed once in buffer 3, followed by 3 washes in dH₂O to removed SDS. Sacculi were responded in 0.1M NaOH and incubated for 16 h at room temperature at 1,400 rpm. Following the incubation, the sacculi were centrifuged at 16,000g, leaving the teichoic acids in the supernatant. 250 µl of 1 M Tris-HCL pH 6.8 was added to neutralise the NaOH and stored at -20°C.

WTA was also precipitated from the supernatant of overnight culture by adding 3 volumes of 95% ethanol and incubation at 4°C for 2 h. Precipitated material was separated by centrifugation at 16,000 g for 15 min, washed once in 70% ethanol and resuspended in 100 mM Tris-HCL (pH 7.5) containing 5 mM CaCl₂, 25 mM MgCl₂, DNase (10 µg/ml) and RNase (50 µg/ml) and incubated for 3 h at 37°C. The enzymes were heat inactivated at 95°C for 3 min.

The supernatant WTA preparations were similarly stored at -20°C before being analysed by PAGE.

Wta page

WTA preparations were separated on tricine polyacrylamide gels using a BioRad tetra cell according to a previously described method⁽⁵⁶⁾. The gels were separated at 4°C using a constant amperage of 40 mA under constant stirring until the dye front reached the bottom. Gels were washed 3 times in MilliQ H_2O followed by staining in 1 mg/ml Alcian blue overnight. Gels were subsequently destained in MilliQ H_2O , until the WTA became visible and finally imaged.

Arachidonic acid supernatant conditioning

Overnight cultures of JE2, *tcaA*, and *lcpA* mutants were pelleted, and the supernatant saved. Growth inhibition assays were subsequently performed by adding 20 μl of $\text{OD}_{600\text{nm}}$ 0.1 bacterial suspension to 180 μl 10% overnight supernatant diluted in fresh MHB++ containing doubling concentrations of arachidonic acid (Sigma). Purified WTA extracts were also added to the growth media at a final concentration of 2%. The ability of the bacteria to survive the arachidonic acid was determined by quantifying bacterial growth ($\text{OD}_{600\text{nm}}$) following 24 h at 37°C using a CLARIOstar plate reader (BMG Labtech).

Cytochrome C binding assay

A cytochrome c binding assay was used to measure the relative surface charge of the bacteria⁽⁵⁷⁾. Briefly, overnight cultures were normalized to an $\text{OD}_{600\text{nm}}$ of 8. The bacterial suspensions were washed twice in MOPS buffer (20 mM pH 7.0) and finally resuspended in 200 μl of MOPS buffer. Samples were then combined with 50 μl of cytochrome C (equine heart Sigma, 2.5 mg/ml in MOPS buffer) and incubated for 10 min at room temperature. Finally, samples were pelleted (16,000 $\times g$ for 1 min) and 200 μl of supernatant read for absorbance at $\text{Abs}_{530\text{nm}}$ using a SUNRISE Tecan microplate reader.

Construction of a TcaA reporter fusion

A *tcaA* promoter-*gfp* fusion (pSB2019:*tcaA*) was constructed to determine expression of *tcaA* in response to several antimicrobial components of serum. A region of 289 bp upstream of the *tcaA* gene⁽⁵⁸⁾ was amplified by PCR from JE2 genomic DNA using the primers *tcaA_promoter* FW 5'-atatgaattcagttatagaagtcacatca -3' and *tcaA_promoter* RV 5'-atatccccgggtttcacctcaattctgttct-3'. The pSB2019 vector was prepared by digesting pSB2031⁽⁵⁹⁾ from a previous study with EcoRI and SmaI to remove the RNAPIII P3 promoter. The *tcaA* promoter region was also digested with EcoRI and SmaI and ligated into pSB2019 using T4 DNA ligase (NEB). This was transformed into DC10B⁽³⁴⁾, a strain of *E. coli* which mimics the adenine methylation profile of some *S. aureus* clonal complexes (including CC8 and CC22). The plasmid was then extracted and transformed into final strains via electroporation.

TcaA induction assay

S. aureus strains carrying the pSB2019:*tcaA* plasmid were grown overnight in TSB with 10 $\mu\text{g}/\text{ml}$ chloramphenicol. Each strain was then normalized to an $\text{OD}_{600\text{nm}}$ of 0.05 in fresh TSB and subcultured to an $\text{OD}_{600\text{nm}}$ of 0.5-0.6. Cultures were washed in PBS and concentrated to an $\text{OD}_{600\text{nm}}$ of 1 in PBS. 100 μl of bacteria was combined with 100 μl of the appropriate antimicrobial compound (arachidonic acid or LL-37) in a black 96-well plate.

GFP Fluorescence (485_{nm} excitation/520_{nm} emission/1000 gain) was measured in a PHERAstar FSX plate reader (BMG Labtech) over 2.5 h (readings every 30 min with 200 rpm shaking).

Lysostaphin turbidity assay

Overnight cultures were back diluted to an OD_{600nm} of 0.05 in 20 mL of fresh TSB and grown to an OD_{600nm} 0.5-0.7. Cultures were normalised to give 1 ml of OD_{600nm} 0.6. Lysostaphin was subsequently added to give a final concentration of 0.5 µg/mL. 200 µL of each strain was then added to a 96-well plate and incubated for 3 h at 37°C in a CLARIOstar plate reader. OD_{600nm} readings were taken every 10 min (500 rpm shaking before readings). Values were blank corrected according to 200 µL of PBS. The PBP4::*tn* mutant was included as a control.

Triton-X100 induced autolysis assay

Overnight cultures were back diluted to an OD_{600nm} of 0.05 in 20 mL of fresh TSB and grown to an OD_{600nm} 0.5-0.7. Cells were washed once in ice cold water (13,000 rpm 1 min) and resuspended in autolysis buffer (water containing 0.1% Triton X-100) to give an OD_{600nm} of 1. 200 µL of each strain was then added to a 96-well plate alongside 200 µL of strains resuspended in water as a negative control and 200 µL of water as a blank. The *atl*::*tn* strain was used as a positive control. Strains were grown for 6 h at 37°C in a CLARIOstar plate reader. OD_{600nm} readings were taken every 30 min (500 rpm shaking before readings). The rate of autolysis was calculated as follows; (OD_{t0}-OD_{tn}/OD_{t0}).

Transmission electron microscopy

S. aureus strains JE2 and the TcaA mutant were pelleted in microfuge tubes and fixed by resuspending in 2.5% glutaraldehyde in cacodylate buffer (pH 7.3) kept at fridge temperatures until fixation was complete and then stored in the fridge. Pellets were resuspended in a BSA/glutaraldehyde gel at 10-20°C which sets after the cells were recentrifuged into a pellet. The pellets were postfixed with osmium ferrocyanide/osmium tetroxide mix in cacodylate buffer, *en bloc* stained with uranyl acetate (2%) and Walton's lead aspartate solutions, prior to dehydration in ethanol and infiltration with propylene oxide and Epon resin mix. Embedded blocks were polymerised for 24-48 hours at 60°C. Sections (70nm) were cut on a Leica UC7 ultramicrotome and imaged using a FEI Tecnai T12 microscope.

In vivo intra-venous challenge model

For survival studies, C57/Bl6 mice were injected with 5X10⁽⁷⁾ CFU of JE2 or *tcaA*::*tn* via the tail vein. Mice were culled at specific time points post challenge and blood collected by cardiac puncture. Blood was diluted in sterile PBS and plated on TSA to determine CFU/mL. For the mixed infection bacteremia model, female, 7-8 week-old, C57BL/6NCr1 mice (Charles River Laboratories) were used. Bacteria were prepared as described previously⁽⁶⁰⁾. Briefly, 1:100 dilutions of overnight bacterial cultures were grown to mid-log phase (~2h) in TSB with shaking at 180 r.p.m. at 37 °C. Bacteria were then harvested, washed with PBS and adjusted spectrophotometrically at OD_{600nm} to obtain the desired bacterial concentration of ~4.8 × 10⁽⁸⁾ CFU/mL. A 50:50 mixture of JE2 and *tcaA*::*tn* were made and 100 µl was injected intravenously via the tail vein. The final CFU for each strain per mouse was ~2.4 × 10⁽⁷⁾ CFU. After 48 hours, terminal cardiac bleeds were performed on anesthetized mice and whole blood was transferred into heparin tubes (Sarstedt) and mixed to prevent coagulation. Mice

onto TSA plates with and without erythromycin (5 µg/ml) for bacterial enumeration. The CFU of JE2 was calculated by subtracting CFU on TSA with erythromycin (*tcaA::tn* only) from CFU on TSA plates (JE2 and *tcaA::tn*).

Ethics statement

C57/Bl6 mice were bred in-house in Trinity College Dublin and C57BL/6NCrl mice were purchased from Charles River Laboratories. Mice were housed under specific pathogen-free conditions at the Trinity College Dublin Comparative Medicines unit and maintained under pathogen-free conditions in an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited animal facility in NIAID, NIH, respectively. All mice were female and used at 6–8 weeks. All animal experiments were conducted in accordance with the recommendations and guidelines of the health product regulatory authority (HPRA), the competent authority in Ireland and in accordance with protocols approved by Trinity College Dublin Animal Research Ethics Committee and according to the regulations of NIAID's Division of Intramural Research Animal Care and Use Committee (DIR ACUC), animal study proposal LB1E. For the human serum collection, all healthy volunteers provided written informed consent and all methods and experimental protocols were carried out in accordance with the recommendations of the University of Bath, Research Ethics Approval Committee for Health. The present study was approved by the University of Bath, Research Ethics Approval Committee for Health [reference: EP 18/19 108].

Statistics

Paired two-tailed student t-test or One-way ANOVA (GraphPad Prism v9.0) were used to analyse the observed differences between experimental results. A *p*-value <0.05 was considered statistically significant.

Acknowledgements

We would like to thank Prof. Mark Jepson, Chris Neal and Lorna Hogdson at the Wolfson Bioimaging Suite. We would also like to thank Eric Skaar and William Beavers for providing the *lcpA* mutant.

Funding information

EJAD was funded on a studentship provided by the School of Cellular and Molecular Medicine, University of Bristol. NP is funded on a BBSRC SWBio DTOP PhD Studentship. DA is funded by a PhD studentship awarded by the Saudi Arabian Cultural Bureau. RCMs and RMM are both Wellcome Trust Investigators (Grant reference numbers: 212258/Z/18/Z and 202846/Z/16/Z). MO is supported by the Intramural Research Program of the National Institutes of Allergic and Infectious Diseases (NIAID), US National Institutes of Health (NIH), project number ZIA AI000904. ML acknowledges funding from the Academy of Medical Sciences (SBF006\1023).

Conflict of Interests

we the authors declare no conflict of interest associated with the work described in this manuscript

Author Contributions

EJAD developed the methodology, conceptualized and performed the experiments, analysed data, provided supervisory support and contributed to writing the manuscript. NP developed methodology and performed experiments. TB developed methodology, performed experiments and provided supervisory support. DA performed experiments. ML provided materials, analysed data and provided supervisory support. MR developed methodology, analysed data and contributed to writing the manuscript. GYCC, RCH, RL performed serum resistance experiments with mouse serum and murine bacteraemia experiments and GYCC analyzed data. MO provided supervisory support and provided materials. EOB performed experiments and analysed data, RMM provided materials, analysed data and contributed to writing the manuscript. RCM conceptualized the project, provided materials, provided supervisory support, analysed data and contributed to writing the manuscript.

References

1. Gordon R.J. , Lowy F.D. (2008) **Pathogenesis of methicillin-resistant *Staphylococcus aureus* infection** *Clin Infect Dis* **5**:–9
2. Lowy F.D. (1998) ***Staphylococcus aureus* infections** *N Engl J Med* **339**:520–32
3. Powers M.E. , Bubeck Wardenburg J. (2014) **Igniting the fire: *Staphylococcus aureus* virulence factors in the pathogenesis of sepsis** *PLoS Pathog.* **10**:
4. Abdelnour A. , Arvidson S. , Bremell A. , Ryden C. , Tarkowski A. (1993) **The accessory gene regulator (*agr*) controls *Staphylococcus aureus* virulence in a murine arthritis model** *Infect Immun* **61**:3879–85
5. Cheung A.L. (1994) **Diminished virulence of a *sar*–/*agr*–mutant of *Staphylococcus aureus* in the rabbit model of endocarditis** *J Clin Invest* **94**:1815–22
6. Rose H.R. (2015) **Cytotoxic Virulence Predicts Mortality in Nosocomial Pneumonia Due to Methicillin-Resistant *Staphylococcus aureus*** *J Infect Dis* **211**:1862–74
7. Laabei M. (2015) **Evolutionary Trade-Offs Underlie the Multi-faceted Virulence of *Staphylococcus aureus*** *PLoS Biol* **13**:
8. Kaash A.J. (2014) ***Staphylococcus aureus* bloodstream infection: a pooled analysis of five prospective, observational studies** *J Infect* **68**:242–51

9. Levy O. (2000) **Antimicrobial proteins and peptides of blood: templates for novel antimicrobial agents** *Blood* **96**:2664–72
10. Kenny J.G. (2009) **The Staphylococcus aureus Response to Unsaturated Long Chain Free Fatty Acids: Survival Mechanisms and Virulence Implications** *PLoS One* **4**:
11. Beavers W.N. (2019) **Arachidonic Acid Kills Staphylococcus aureus through a Lipid Peroxidation Mechanism** *mBio* **10**:5
12. Das U.N. (2018) **Arachidonic acid and other unsaturated fatty acids and some of their metabolites function as endogenous antimicrobial molecules: A review** *J Advanc Res* **11**:57–66
13. Laabei M. (2014) **Predicting the virulence of MRSA from its genome sequence** *Genome Res* **24**:839–49
14. Recker M. (2017) **Clonal differences in Staphylococcus aureus bacteraemia-associated mortality** *Nat Microbiol* **2**:1381–1388
15. Yokoyama M. (2018) **Epistasis analysis uncovers hidden antibiotic resistance-associated fitness costs hampering the evolution of MRSA** *Genome Biol* **19**:94
16. Stevens E. (2022) **Targeted control of toxin production by a mobile genetic element in Streptococcus pneumoniae** *Microb Genom* **8**:784
17. Altwiley D. (2021) **A Functional Menadione Biosynthesis Pathway is Required for Capsule Production by Staphylococcus aureus** *Microbiology* **167**:1108
18. Douglas E.J. , Duggan S. , Brignoli T. , Massey RC. (2021) **The MpsB protein contributes to both the toxicity and immune evasion capacity of Staphylococcus aureus** *Microbiology* **167**:1096
19. Peschel A. (1999) **Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides** *J Biol Chem* **274**:8405–10
20. Ernst C.M. , Peschel A. (2011) **Broad-spectrum antimicrobial peptide resistance by MprF-mediated aminoacylation and flipping of phospholipids** *Mol Microbiol* **80**:290–9
21. Hwang-Soo J. , Otto M. (2015) **Mechanisms of resistance to antimicrobial peptides in staphylococci** *Biochimica et Biophysica Acta (BBA) – Biomembranes* **1848**:3055–3061
22. Kohler T. , Weidenmaier C. , Peschel A. (2009) **Wall Teichoic Acid Protects Staphylococcus aureus against Antimicrobial Fatty Acids from Human Skin** *J Bacteriol* **191**:4482–4484
23. Fey P.D. (2013) **A genetic resource for rapid and comprehensive phenotype screening of nonessential Staphylococcus aureus genes** *mBio* **4**:

24. Brandenberger M. (2000) **Inactivation of a novel three-cistronic operon *tcaR-tcaA-tcaB* increases teicoplanin resistance in *Staphylococcus aureus*** *Biochim Biophys Acta* **1523**:135–9
25. Xia G. , Kohler T. , Peschel A. (2010) **The wall teichoic acid and lipoteichoic acid polymers of *Staphylococcus aureus*** *Int J Med Microbiol* **300**:148–54
26. Fujita Y. , Fujita T. (1987) **The gluconate operon *gnt* of *Bacillus subtilis* encodes its own transcriptional negative regulator** *Proc Natl Acad Sci U S A* **84**:4524–8
27. Li K.H. (2017) **Biological Functions of *ilvC* in Branched-Chain Fatty Acid Synthesis and Diffusible Signal Factor Family Production in *Xanthomonas campestris*** *Front Microbiol* **8**:2486
28. Shen Z. , Han J. , Wang Y. , Sahin O. , Zhang Q. (2013) **The Contribution of *ArsB* to Arsenic Resistance in *Campylobacter jejuni*** *PLoS One* **8**:
29. Rismondo J. , Percy M.G. , Gründling A. (2018) **Discovery of genes required for lipoteichoic acid glycosylation predicts two distinct mechanisms for wall teichoic acid glycosylation** *J Biol Chem* **293**:3293–3306
30. Hemilä H. (1991) **Lipoamide dehydrogenase of *Staphylococcus aureus*: nucleotide sequence and sequence analysis** *Biochim Biophys Acta* **1129**:119–23
31. Jumper J. (2021) **Highly accurate protein structure prediction with AlphaFold** *Nature* **596**:583–9
32. Ma B. , Nussinov R. (2007) **Trp/Met/Phe hot spots in protein-protein interactions: potential targets in drug design** *Curr Top Med Chem* **7**:999–1005
33. Waldron D.E. , Lindsay J.A. (2006) **Sau1: a Novel Lineage-Specific Type I Restriction-Modification System That Blocks Horizontal Gene Transfer into *Staphylococcus aureus* and between *S. aureus* Isolates of Different Lineages** *J. Bacteriol* **188**:5578–85
34. Monk I.R. (2012) **Transforming the Untransformable: Application of Direct Transformation To Manipulate Genetically *Staphylococcus aureus* and *Staphylococcus epidermidis*** *mBio* **3**:–11
35. Maki H. , McCallum N. , Bischoff M. , Wada A. , Berger-Bächi B. (2004) ***tcaA* inactivation increases glycopeptide resistance in *Staphylococcus aureus*** *Antimicrob Agents Chemother* **48**:1953–9
36. Schlag M. (2010) **Role of staphylococcal wall teichoic acid in targeting the major autolysin *Atl*** *Mol Microbiol* **75**:864–73
37. Brown S (2012) **Methicillin resistance in *Staphylococcus aureus* requires glycosylated wall teichoic acids** *Proc Natl Acad Sci U S A* **109**:18909–14

38. Kurokawa K. (2013) **Glycoepitopes of staphylococcal wall teichoic acid govern complement-mediated opsonophagocytosis via human serum antibody and mannose-binding lectin** *J Biol Chem* **288**:30956–68
39. Wanner S. (2017) **Wall teichoic acids mediate increased virulence in *Staphylococcus aureus*** *Nature Microbiol* **2**:16257
40. Weidenmaier C. (2005) **Lack of Wall Teichoic Acids in *Staphylococcus aureus* Leads to Reduced Interactions with Endothelial Cells and to Attenuated Virulence in a Rabbit Model of Endocarditis** *Journal Infect Dis* **191**:1771–7
41. Monk IR. , Casey P.G. , Cronin M. , Gahan C.G. , Hill C. (2008) **Development of multiple strain competitive index assays for *Listeria monocytogenes* using pIMC; a new site-specific integrative vector** *BMC Microbiol* **13**:96
42. Steidl R. (2008) ***Staphylococcus aureus* cell wall stress stimulon gene-lacZ fusion strains: potential for use in screening for cell wall-active antimicrobials** *Antimicrob Agents Chemother* **52**:2923–5
43. Utaida S. (2003) **Genome-wide transcriptional profiling of the response of *Staphylococcus aureus* to cell-wall-active antibiotics reveals a cell-wall-stress stimulon** *Microbiology* **149**:2719–32
44. Levin BR , Bull JJ. (1994) **Short-sighted evolution and the virulence of pathogenic microorganisms** *Trends Microbiol* **2**:76–81
45. Corrigan R.M. , Foster T.J. (2009) **An improved tetracycline-inducible expression vector for *Staphylococcus aureus*** *Plasmid* **61**:126–9
46. Kreiswirth B. N. (1983) **The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage** *Nature* **305**:709–712
47. Horsburgh M. J. (2002) **σ B Modulates Virulence Determinant Expression and Stress Resistance: Characterization of a Functional rsbU Strain Derived from *Staphylococcus aureus* 8325-4** *J Bacteriol* **184**:5457–5467
48. Hawiger J. , Niewiarowski S. , Gurewich V. , Thomas D. P. (1970) **Measurement of fibrinogen and fibrin degradation products in serum by staphylococcal clumping test** *Lab Clin Med* **75**:93–108
49. Diep B. A. (2006) **Complete genome sequence of USA300, an epidemic clone of community-acquired methicillin-resistant *Staphylococcus aureus*** *The Lancet* **367**:731–739
50. Schuster C. F. (2020) **High-throughput transposon sequencing highlights the cell wall as an important barrier for osmotic stress in methicillin resistant *Staphylococcus aureus* and underlines a tailored response to different osmotic stressors** *Mol Microbiol* **113**:699–717

51. Krausz K.L. , Bose J.L. (2016) **Bacteriophage Transduction in *Staphylococcus aureus*: Broth-Based Method** *Methods Mol Biol* **1373**:63–8
52. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) undefined (2003) **Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution** *Clin Microbiol Infect* **9**:
53. Duggan S. (2020) **A Small Membrane Stabilizing Protein Critical to the Pathogenicity of *Staphylococcus aureus*** *Infect Immun* **88**:–20
54. Livak K. J. , Schmittgen T. D. (2001) **Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2- $\Delta\Delta$ CT Method** *Methods* **25**:402–408
55. Kho K. , Meredith T. (2018) **Extraction and Analysis of Bacterial Teichoic Acids** *Bio Protoc* **8**:
56. Brignoli T. (2022) **Wall Teichoic Acids Facilitate the Release of Toxins from the Surface of *Staphylococcus aureus***
<https://doi.org/10.1128/spectrum.01011-22>
57. Douglas E. J. A. (2022) **Antibacterial activity of novel linear polyamines against *Staphylococcus aureus*** *Front Microbiol* **13**:
58. Dengler V. , Meier P. S. , Heusser R. , Berger-Bächi B. , McCallum N. (2011) **Induction kinetics of the *Staphylococcus aureus* cell wall stress stimulon in response to different cell wall active antibiotics** *BMC Microbiol* **11**:16
59. Qazi S. N. A. (2001) **agr Expression Precedes Escape of Internalized *Staphylococcus aureus* from the Host Endosome** *Infect Immun* **69**:7074–7082
60. Nguyen T. H. (2022) **Rapid pathogen-specific recruitment of immune effector cells in the skin by secreted toxins** *Nat Microbiol* **7**:62–72
61. Bae J. S. (2021) **Contribution of Staphylococcal Enterotoxin B to *Staphylococcus aureus* Systemic Infection** *J Infect Dis* **223**:1766–1775

Author information

1. Edward J.A. Douglas

School of Cellular and Molecular Medicine, University of Bristol, Bristol, BS8 1TD, UK,
Department of Life Sciences, University of Bath, BA2 7AY, UK

2. Nathanael Palk

School of Cellular and Molecular Medicine, University of Bristol, Bristol, BS8 1TD, UK

3. Tarcisio Brignoli

School of Cellular and Molecular Medicine, University of Bristol, Bristol, BS8 1TD, UK,
Department of Biosciences, Università degli Studi di Milano, Milan, Italy

4. Dina Altwiley

School of Cellular and Molecular Medicine, University of Bristol, Bristol, BS8 1TD, UK

5. Marcia Boura

School of Cellular and Molecular Medicine, University of Bristol, Bristol, BS8 1TD, UK

6. Maisem Laabei

Department of Life Sciences, University of Bath, BA2 7AY, UK
ORCID iD: [0000-0002-8425-3704](https://orcid.org/0000-0002-8425-3704)

7. Mario Recker

Centre for Ecology and Conservation, University of Exeter, Penryn Campus, TR10 9FE,
UK, Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany
ORCID iD: [0000-0001-9489-1315](https://orcid.org/0000-0001-9489-1315)

8. Gordon Y.C. Cheung

Laboratory of Bacteriology, National Institute of Allergy and Infectious Diseases
(NIAID), US National Institutes of Health (NIH), Bethesda, Maryland, USA

9. Ryan Liu

Laboratory of Bacteriology, National Institute of Allergy and Infectious Diseases
(NIAID), US National Institutes of Health (NIH), Bethesda, Maryland, USA

10. Roger C. Hsieh

Laboratory of Bacteriology, National Institute of Allergy and Infectious Diseases
(NIAID), US National Institutes of Health (NIH), Bethesda, Maryland, USA

11. Michael Otto

Laboratory of Bacteriology, National Institute of Allergy and Infectious Diseases
(NIAID), US National Institutes of Health (NIH), Bethesda, Maryland, USA

12. Eoin O'Brien

Host Pathogen Interactions Group, School of Biochemistry and Immunology, Trinity
College Dublin, Dublin 2, Ireland

13. Rachel M. McLoughlin

Host Pathogen Interactions Group, School of Biochemistry and Immunology, Trinity
College Dublin, Dublin 2, Ireland

14. Ruth C. Massey

School of Cellular and Molecular Medicine, University of Bristol, Bristol, BS8 1TD, UK,
Schools of Microbiology and Medicine, University College Cork, and APC Microbiome
Ireland, Cork, Ireland

For correspondence:

ruth.massey@bristol.ac.uk
ORCID iD: [0000-0002-8154-4039](https://orcid.org/0000-0002-8154-4039)

Editors

Reviewing Editor

Vaughn Cooper

University of Pittsburgh, United States of America

Senior Editor

Arturo Casadevall

Johns Hopkins Bloomberg School of Public Health, United States of America

Reviewer #1 (Public Review):

In this manuscript by Douglas et al, the investigative team seeks to identify *Staphylococcus aureus* genes (and associated polymorphisms) that confer altered susceptibility to human serum, with the hypothesis that such genes might contribute to the propensity of a strain to cause bacteremia, invasive disease, and/or death. Using an innovative GWAS-like approach applied to a bank of over 300 well-characterized clinical *S. aureus* isolates, the authors discover SNPs in seven different staphylococcal genes that confer increased survival in the setting of serum exposure. The authors then mainly focus on one gene, *tcaA*, and illustrate a potential mechanism whereby modification of peptidoglycan structure and WTA display leads to altered susceptibility to serum, serum-derived antimicrobial compounds, and antibiotics. One particularly significant finding is that the identified *tcaA* SNP is significantly associated with patient mortality, in that patients infected with the SNP bearing isolate are less likely to die from infection. It is therefore hypothesized that this SNP represents an adaptive mutation that promotes serum survival while decreasing virulence and host mortality. In a murine model of infection, the strain bearing the WT allele of *tcaA* is significantly more virulent than the *tcaA* mutant, suggesting that the role of *tcaA* in bacteremia is infection-phase dependent.

This manuscript has many strengths. The triangulation of genomic analysis, patient outcomes data, and in vitro and in vivo mechanistic testing adds to the significance of the findings in terms of human disease. Testing the impact of mutating *tcaA* in multiple staphylococcal lineages and backgrounds also increases the rigor of the study. The identification of bacterial loci that impact susceptibility to both host antimicrobial compounds and commonly used antibiotics is also a strength of this work, given the evolutionary and treatment implications for such genes.

One moderate weakness is that the impact of the identified SNP in *tcaA* is only tested in some of the assays, whereas the majority of the testing is performed with a whole gene knockout. Additionally, for some experiments, rigor is lacking in that statistical measures are not deployed to support the conclusions of biologically meaningful changes based on data

with very modest differences between groups. In some cases this results in more speculative conclusions that will require further testing to validate. Finally, there are instances of inter-experiment variability that require further explanation. All in all, this is an exciting manuscript that will be of interest to the broader research communities focused on staphylococcal pathogenesis, bacterial evolution, and host-pathogen interactions, as well as to clinicians who care for patients with invasive staphylococcal infection.

Reviewer #2 (Public Review):

The authors embarked on a study to identify SNPs in clinical isolates of *S. aureus* that influence sensitivity to serum killing. Through a phenotypic screen of 300 previously sequenced *S. aureus* bacteremia (SAB) isolates, they identified ~40 SNPs causing altered serum survival. The remainder of the study focuses on *tcaA*, a gene with unknown function. They show that when *tcaA* is disrupted, it results in increased resistance to glycopeptides and antimicrobial components of human serum.

They perform an elegant series of experiments demonstrating how a *tcaA* knockout is more resistant to killing by whole serum, arachidonic acid, LL-37 and HNP-1. They provide compelling evidence that in the absence of *tcaA* resistance to arachidonic acid is mediated through release of wall teichoic acids from the cell wall, which acts as a decoy and sequesters the fatty acid.

Similarly, they suggest that resistance to cationic antimicrobial peptides is through alteration of the net charge of the cell wall due to loss of negatively charged WTAs based on reduced cytochrome C binding.

They continue to show that *tcaA* is induced in the presence of human serum, which causes increased resistance to the glycopeptide teichoplanin.

They propose that *tcaA* disruption causes altered cell wall structure based on morphologic changes on TEM and increased sensitivity to lysostaphin and increased autolysis via triton x-100 assay.

5, Finally, they propose that *tcaA* influences mortality in SAB based on raw differences in 30-day mortality. Interestingly they do decreased fitness during murine bacteremia model compared to wild-type.

Strengths:

1. The manuscript is well-written and easy to follow
2. The identification of SNPs leading to altered serum killing is convincing and valuable data
3. The mechanism for *tcaA*-mediated resistance to arachidonic acid and AMPs is compelling and novel
4. The murine infection data demonstrating that *tcaA* mutants exhibit reduced virulence is important data

Weaknesses:

1. Some of the conclusions are not supported by the data shown (either missing or incomplete)
2. The authors conclude that *tcaA* mutants show reduced peptidoglycan crosslinking. This conclusion is based on qualitative TEM images and increased sensitivity to lysostaphin/autolysis. While these data are suggestive, it is difficult to draw such a conclusion without analysis of the cell wall by LC-MS (such as 2023 eLife. <http://doi.org/10.1371/journal.ppat.1009468>).
3. The authors conclude "TcaA contributes to increased disease severity in mice and

humans". While it seems biologically plausible that a polymorphism known to increase glycopeptide MIC affects mortality, the human data presented is based on raw 30-day mortality numbers. It is misleading to make the association with mortality without adjusting for confounding variables known to influence mortality in SAB (e.g. age, comorbidities, presence of sepsis, endocarditis, duration of bacteremia). Also, with just 12 patients in the SNP group, this is likely underpowered to detect any difference.

Overall, I think this is a good submission and the majority of their conclusions are supported by the data. The mechanism behind the clinically relevant *tcaA* mutation is important, given its known role in glycopeptide resistance and therefore likely clinical outcomes. This manuscript would benefit with the inclusion of some additional experiments to help support their finding.

Reviewer #3 (Public Review):

In this manuscript by Douglas et al., the authors used a functional genomics approach to understand how *Staphylococcus aureus* survives in the bloodstream to cause bacteraemia. They identified seven novel genes that affect serum survival. The study focused on *tcaA*, a gene associated with resistance to the antibiotic teicoplanin and is activated when exposed to serum and plays a role in producing a critical virulence factor called wall teichoic acids (WTA) in the cell envelope. This protein affects the bacteria's sensitivity to cell wall attacking agents, human defense fatty acids, and antibiotics, as well as autolytic activity and lysostaphin sensitivity. The data in this study suggested that TcaA play a role in the ligation or retention of WTA within the cell wall. However, more work is needed to clarify that part. Interestingly, despite making the bacteria more vulnerable to serum killing, *tcaA* contributes to *S. aureus* virulence by altering the cell wall architecture, as demonstrated by the wild type strain outcompeting the *tcaA* mutant in a Mouse Co-infection model. The study raises an important point that TcaA in *S. aureus* may represent a system balancing two scenarios: it makes the bacteria more susceptible to serum killing, potentially limiting bacteraemia and providing long-term benefits between hosts; however, once established in the bloodstream, the bacteria survive and thrive, causing successful bacteraemia, as per the short-sighted evolution of virulence hypothesis. This duality highlights the complex interplay between within-host and between-host fitness in bacterial evolution. I strongly suggest creating a graphical abstract to illustrate the complex relationship between within-host and between-host fitness scenarios involving TcaA. Having this visual representation in the discussion will enhance comprehension and provide a concise summary of the complex system for the reader.

In this manuscript, the authors achieved their aims, and the results support their conclusions. This work will be fundamental for understanding this complex system and for developing novel therapeutics and vaccines for *S. aureus*.